Text size :

Biffoli (Mimit): “Europe must improve its position in life sciences”

ADNKRONOS

November 10, 2026

Rome, Nov 10. (Adnkronos Health) – “The Italian Life Sciences system is quite competitive, although Europe’s position is intermediate compared to China and the United States and therefore needs to be recovered.” This was stated today in Rome by Claudia Biffoli, director of the Biotechnology and Pharmaceutical division of the General Directorate for Emerging Technologies of the Ministry of Enterprises and Made in Italy, participating in the XXI edition of the Meridiano Sanità Forum ‘Healthcare and life sciences: governing transitions, building the future’, the think tank of The European House – Ambrosetti.

“Italy has a very high-level background, which must necessarily be enhanced. Therefore, incentive policies and investment attraction policies are needed, as well as regulatory simplification, also in line with the indications emerging at a European level. This is an opportunity that we must necessarily seize,” explains Biffoli.

“The MFN issue,” meaning the drug pricing policy model launched by the United States to reduce its pharmaceutical spending, according to Biffoli, “has shaken the sector and challenged paradigms that were moving very slowly. It can also represent an opportunity, because it helps us redesign processes and understand that access to innovation must be accelerated, otherwise investments will shift to other territories. At this moment we see some signs of slowdown but all the conditions for recovery are there.”

Jiji Press

Related

Page TOP